494 related articles for article (PubMed ID: 31047727)
1. Tumor mutation burden, DNA mismatch repair status and checkpoint immunotherapy markers in primary and relapsed malignant rhabdoid tumors.
Abro B; Kaushal M; Chen L; Wu R; Dehner LP; Pfeifer JD; He M
Pathol Res Pract; 2019 Jun; 215(6):152395. PubMed ID: 31047727
[TBL] [Abstract][Full Text] [Related]
2. Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma.
He M; Abro B; Kaushal M; Chen L; Chen T; Gondim M; Yan W; Neidich J; Dehner LP; Pfeifer JD
Hum Pathol; 2020 Jun; 100():15-23. PubMed ID: 32387103
[TBL] [Abstract][Full Text] [Related]
3. Programmed Death Ligand 1 Expression and Related Markers in Pleuropulmonary Blastoma.
Alipour Z; Schultz KAP; Chen L; Harris AK; Gonzalez IA; Pfeifer J; Hill DA; He M; Dehner LP
Pediatr Dev Pathol; 2021; 24(6):523-530. PubMed ID: 34266329
[TBL] [Abstract][Full Text] [Related]
4. A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases.
Huang RSP; Haberberger J; Severson E; Duncan DL; Hemmerich A; Edgerly C; Ferguson NL; Williams E; Elvin J; Vergilio JA; Killian JK; Lin DI; Tse J; Hiemenz M; Owens C; Danziger N; Hegde PS; Venstrom J; Alexander B; Ross JS; Ramkissoon SH
Mod Pathol; 2021 Feb; 34(2):252-263. PubMed ID: 32884129
[TBL] [Abstract][Full Text] [Related]
5. Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers.
Forrest SJ; Al-Ibraheemi A; Doan D; Ward A; Clinton CM; Putra J; Pinches RS; Kadoch C; Chi SN; DuBois SG; Leavey PJ; LeBoeuf NR; Mullen E; Collins N; Church AJ; Janeway KA
Clin Cancer Res; 2020 Jun; 26(12):2882-2890. PubMed ID: 32122923
[TBL] [Abstract][Full Text] [Related]
6. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
7. A dynamic mutational landscape associated with an inter-regionally diverse immune response in malignant rhabdoid tumour.
Yasui H; Valind A; Karlsson J; Pietras C; Jansson C; Wille J; Romerius P; Backman T; Gisselsson D
J Pathol; 2020 Sep; 252(1):22-28. PubMed ID: 32542645
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
9. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016
[TBL] [Abstract][Full Text] [Related]
10. Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?
Özcan D; Lade-Keller J; Tramm T
Pathol Res Pract; 2021 Oct; 226():153606. PubMed ID: 34530255
[TBL] [Abstract][Full Text] [Related]
11. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors.
Hoot AC; Russo P; Judkins AR; Perlman EJ; Biegel JA
Am J Surg Pathol; 2004 Nov; 28(11):1485-91. PubMed ID: 15489652
[TBL] [Abstract][Full Text] [Related]
13. Response to PD-1 inhibitor in SMARCB1‑deficient undifferentiated rectal carcinoma with low TMB, proficient MMR and BRAF V600E mutation: a case report and literature review.
Shen W; Pan Y; Zou S
Diagn Pathol; 2024 Jan; 19(1):11. PubMed ID: 38217014
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers.
Nazha B; Zhuang T; Wu S; Brown JT; Magee D; Carthon BC; Kucuk O; Nabhan C; Barata PC; Heath EI; Ryan CJ; McKay RR; Master VA; Bilen MA
Cancer; 2023 Dec; 129(24):3884-3893. PubMed ID: 37565840
[TBL] [Abstract][Full Text] [Related]
16. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
Chae YK; Davis AA; Raparia K; Agte S; Pan A; Mohindra N; Villaflor V; Giles F
Clin Lung Cancer; 2019 Mar; 20(2):88-96.e6. PubMed ID: 30425022
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
Garber ST; Hashimoto Y; Weathers SP; Xiu J; Gatalica Z; Verhaak RG; Zhou S; Fuller GN; Khasraw M; de Groot J; Reddy SK; Spetzler D; Heimberger AB
Neuro Oncol; 2016 Oct; 18(10):1357-66. PubMed ID: 27370400
[TBL] [Abstract][Full Text] [Related]
18. Pathology and diagnosis of SMARCB1-deficient tumors.
Margol AS; Judkins AR
Cancer Genet; 2014 Sep; 207(9):358-64. PubMed ID: 25246033
[TBL] [Abstract][Full Text] [Related]
19. Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis and therapeutics.
Jones D; Guan JJ; Calagua C; Hansel DE; Epstein JI; Ye H
Hum Pathol; 2019 Dec; 94():58-63. PubMed ID: 31666198
[TBL] [Abstract][Full Text] [Related]
20. Mutations of the p53 gene in malignant rhabdoid tumors of soft tissue and the kidney: immunohistochemical and DNA direct sequencing analysis.
Kinoshita Y; Shiratsuchi H; Tamiya S; Oshiro Y; Hachitanda Y; Oda Y; Suita S; Tsuneyoshi M
J Cancer Res Clin Oncol; 2001; 127(6):351-8. PubMed ID: 11414195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
